

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|---|----------------------|------------------------|---------------------|
| TRANSMITTAL FORM (to be used for all correspondence after initial filing) | Application Number | 10/035,783 | |
| | Filing Date | December 24, 2001 | |
| | First Named Inventor | Michael GRAUPE et al. | |
| | Art Unit | 1626 | |
| | Examiner Name | SHIAO, Rei Tsang | |
| Total Number of Pages In This Submission | 18 | Attorney Docket Number | USAV2001/0081 US NP |


RECEIVED
CENTRAL FAX CENTER
JAN 04 2005

| ENCLOSURES (Check all that apply) | | |
|--|--|--|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> 1. Form 1449 2. Transmittal of IDS Fee Form </div> |
| Remarks | | |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | | | |
|--------------|---|----------|-------|
| Firm Name | AVENTIS PHARMACEUTICALS INC. | | |
| Signature |  | | |
| Printed name | Joseph ROSSI | | |
| Date | January 04, 2005 | Reg. No. | 47038 |

CERTIFICATE OF TRANSMISSION/MAILING

| | |
|--|---|
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306; Total No. of Pages Transmitted: 18) | |
| Signature |  |
| Typed or printed name | Paul Irvine |
| Date | January 04, 2005 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JAN. 4. 2005 2:51PM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

JAN 04 2005

NO. 1077 P. 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
GRAUPE, et al.

Examiner: Robert Shaio

Art Unit: 1626

Application No.: 10/035,783

Filed: 12/24/2001

Title: **Novel Compounds and
Compositions As Cathespin
Inhibitors**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile to
the Commissioner for Patents, Alexandria, VA 22313, on

January 4, 2005

Date of Transmission

Signature



**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☐ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- ☒ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☒ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The items listed on pages 1 –13 of the attached PTO-1449 have been previously submitted to the Patent Office or cited by the Examiners during the prosecution of the following patents or patent applications commonly owned by the assignees of record of the present case:


U.S. Patent Nos. 6,576,630, 6,506,733, 6,455,502 and 6,492,362; and

U.S. Patent Application Nos. 10/183,128, 10/294,526, 10/719,080, 10/787,367, 10/418,183 and

US02/17922 (PCT application filed in the U.S. receiving office).

Therefore, a copy of the reference is not enclosed with this Information Disclosure Statement.
However, the applicant will furnish a copy of any listed reference, if so requested by the Examiner.

Respectfully submitted,



Joseph D. Rossi, Reg. No. 47,038
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626

Aventis Docket No. USAV2001/0081 US NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
GRAUPE, et al.

Examiner: Robert Shaio

Application No.: 10/035,783

Art Unit: 1626

Filed: 12/24/2001

Title: **Novel Compounds and
Compositions As Cathespin
Inhibitors**


TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile to
the Commissioner for Patents, Alexandria, VA 22313, on

January 4, 2005

Date of Transmission

Signature


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R.
1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. The Commissioner
is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No.
18-1982.

Respectfully submitted,



Joseph D. Rossi, Reg. No. 47,038
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626

Aventis Docket No. USAV2001/0081 US NP

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-96)
 Approved for use through 10/31/99, OMB 0551-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|-------------------------|
| Substitute for form 1449A/PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/035,783 | |
| | | | Filing Date | 12/24/2001 | |
| | | | First Named Inventor | GRAUPE | |
| | | | Group Art Unit | 1626 | |
| | | | Examiner Name | Shaio | |
| Sheet | 1 | of | 13 | Attorney Docket Number | USAV2001/0081 - US - NP |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|--------------------------|----------------------|--------------------------------------|--|--|--|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| | | 4,927,809 | | STUBER, et al. | 05-22-1990 | |
| | | 5,424,325 | | ANDO, et al. | 06-13-1995 | |
| | | 5,486,623 | | ZIMMERMAN, et al. | 01-23-1996 | |
| | | 5,498,616 | | MALLANO, et al. | 03-12-1996 | |
| | | 5,847,135 | | BEMIS, et al. | 12-08-1998 | |
| | | 5,852,007 | | CHATTERJEE, et al. | 12-22-1998 | |
| | | 5,874,424 | | BATCHELOR, et al. | 02-23-1999 | |
| | | 5,998,390 | | RAMAMURTHY, et al. | 12-07-1999 | |
| | | 6,004,933 | | SPRUCE, et al. | 12-21-1999 | |
| | | 6,022,661 | | SCARBOROUGH, et al. | 02-08-2000 | |
| | | 6,114,310 | | CHAMBERLAND, et al. | 09-05-2000 | |
| | | 6,124,393 | | MILLER, et al. | 12-26-2000 | |
| | | 6,255,453 | | GYORKOS | 07-03-2001 | |
| | | 6,353,017 | | ALTMAN, et al. | 03-05-2002 | |
| | | 6,455,502 | | BRYANT, et al. | 09-24-2002 | |
| | | 6,476,026 | | BRYANT, et al. | 11-05-2002 | |
| | | 6,492,382 | | GRAUPE, et al. | 12-10-2002 | |
| | | 6,506,733 | | BUYSSE | 01-14-2003 | |
| | | 6,576,630 | | LINK, et al. | 06-10-2003 | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|--------------------------|-------------------------|---------------------|--------------------------------------|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ³ |
| | | Office ⁴ | Number ⁴ | Kind Code ² (if known) | | | | |
| | | EP | EP 0272671 | | KRANTZ, et al. | 06-29-1988 | | |
| | | EP | EP 0291234 | | EDWARDS, et al. | 11-17-1998 | | |
| | | EP | EP 0355572 | | PAQUES, et al. | 02-28-1990 | | |
| | | EP | EP 0376012 | | ALBRIGHT, et al. | 07-04-1990 | | |
| | | EP | EP 0419683 | | HARA, et al. | 04-03-1991 | | |
| | | EP | EP 0536399 | | OKUBO, et al. | 04-01-1993 | | |
| | | EP | EP 0652009 | | DOVEY, et al. | 10-05-1995 | | |
| | | EP | EP 0754454 | | KOBAYASHI, et al. | 01-22-1997 | | |
| | | JP | JP 06192199 | | RYOICHI, et al. | 07-12-1994 | | |
| | | JP | JP 42009133 | | IRIKURA, et al. | 05-06-1967 | | |

| | |
|-----------------------|--------------------|
| Examiner Signature | Date Considered |
|-----------------------|--------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|-------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | Complete If Known | | |
| | | | Application Number | 10/035,783 | |
| | | | Filing Date | 12/24/2001 | |
| | | | First Named Inventor | GRAUPE | |
| | | | Group Art Unit | 1626 | |
| | | | Examiner Name | Shalo | |
| Sheet | 2 | of | 13 | Attorney Docket Number | USAV2001/0081 - US - NP |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|---|--|----------------|
| Examiner Initials ^a | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Paragraphs or Relevant Figures Appear | T ⁶ |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | | JP | JP 63303868 | | YOSHIDA, et al. | 12-08-1988 | | |
| | | WO | WO 00/48992 | | TUCKER, et al. | 08-24-2000 | | |
| | | WO | WO 00/49007 | | TUCKER, et al. | 08-24-2000 | | |
| | | WO | WO 00/49008 | | TUCKER, et al. | 08-24-2000 | | |
| | | WO | WO 00/51998 | | CYWIN, et al. | 09-08-2000 | | |
| | | WO | WO 00/59881 | | SINGH, et al. | 10-12-2000 | | |
| | | WO | WO 00/69855 | | QUIBELL, et al. | 11-23-2000 | | |
| | | WO | WO 01/09110 | | BEKKALI, et al. | 02-08-2001 | | |
| | | WO | WO 01/19796 | | GRAUPE, et al. | 03-22-2001 | | |
| | | WO | WO 01/19808 | | GRAUPE | 03-22-2001 | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/99. OMB 0661-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|---|---|----|--------------------------|-------------------------|
| Substitute for form 1449B/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/035,783 |
| | | | Filing Date | 12/24/2001 |
| | | | First Named Inventor | GRAUPE |
| | | | Group Art Unit | 1626 |
| | | | Examiner Name | Shaio |
| | | | Attorney Docket Number | USAV2001/0081 - US - NP |
| Sheet | 6 | of | 13 | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issuue number(s), publisher, city and/or country where published. | Y ² |
| | | ADAMS, et al., Potent and Selective Inhibitors of the Proteasom: Dipeptidyl Boronic Acids, Bioorganic & Medicinal Chemistry Letters, 8: 333-338 (1998). | |
| | | ASHWORTH, et al., 4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV, Bioorganic & Med. Chem. Letters, B, Oxford, 6(22):2745-2748 (1996). | |
| | | BERGEMAN, et al., Studies on the reactivity of .alpha.-cyano.alpha.-isocyano alkanooates. Versatile synthons for the assembly of imidazoles, Helv.Chim. ACTA, 62(6):909-918 (1999). | |
| | | BILLSON, et al., The Design and Synthesis of Inhibitors of the Cysteinyl , Bloorg. Med. Chem. Lett. vol. 8, pp. 993-998, 1998 | |
| | | BROMME, et al., Potent Inactivation of Cathepsins S and L , Biol. Chem. Hoppe-Seyler. vol. 375, No. 5, pp. 343-347, 1994. | |
| | | CHATTERJEE, et al., D-Amino Acid Containing, High-Affinity Inhibitors of Recombinant Human Calpain I, Journal of Medicinal Chemistry, vol. 41, No. 15, p: 2663-2666 (1998). | |
| | | COHEN, et al., Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders, Journal of Neuroimmunology, 98: 29-36 (1999). | |
| | | DUFOR, et al., Engineering nitrile hydratase activity into a cysteine protease by a single mutation, Biochemistry, US, Am. Chem. Soc., Easton, PA, 34(50):16382-16388 (1995). | |
| | | EDWARDS, et al., Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl a-Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole, Journal of American Chemical Society, vol. 114, No. 5, p 1854-1863 (1992). | |
| | | EVOLI, et al., abstract only, Drugs, 1996, 52(5), 662-70 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-96)
 Approved for use through 10/31/99, OMB 0651-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|---|---|----|--------------------------|-------------------------|
| Substitute for form 1449B/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/035,783 |
| | | | Filing Date | 12/24/2001 |
| | | | First Named Inventor | GRAUPE |
| | | | Group Art Unit | 1626 |
| | | | Examiner Name | Shaio |
| | | | Attorney Docket Number | USAV2001/0081 - US - NP |
| Sheet | 7 | of | 13 | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | GOUR-BALIN, et al., Inhibition of papain by peptide nitriles: conversion of the nitrile group into other functionalities via the papain:nitrile thiomidate ester adduct, Can. J. of Chem, CA, National Research Council, Ottawa, 69(8):1288-1297 (1991). | |
| | | HALLEGUA, et al., Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, Lupus, 9: 241-251 (2000). | |
| | | HANZLIK, et al., Reversible covalent binding of peptide nitriles to papain, Biochim. Biophys. Acta, vol. 1035, No. 1, 1990, pp. 62-70. | |
| | | HARRIS, et al., Characteristics of a continuous fluorogenic assay for calpain I. Kinetic evaluation of peptide aldehydes, halomethyl ketones and (achalasia) methyl ketones as inhibitors of the enzyme, Chemical Abstracts, 110:7, Bioorg. Med. Chem. Lett, 5(4) 393-398 (1995). | |
| | | HEITMILLER, R.F., abstract only., Semin. Thorac. Cardiovasc. Surg., 1999, 11(1), 41-6 | |
| | | KATRITZKY, et al., Benzotriazole-assisted synthesis of alpha-(acylamino) nitriles and a conceptually novel method for peptide elongation, Chem. Soc., Perkin Trans. 1(7):1853-1857 (1990). | |
| | | KHAMASHTA, et al., Expert. Opin. Investig. Drugs, 2000, 9(7), 1581-83. | |
| | | KRANTZ, et al., Peptidyl (Acyloxy)methyl Ketones and the Quiescent, Biochemistry, vol. 30, pp. 4678-4687, 1991 | |
| | | LEVY, E.G., Baillieres Clin. Endocrinol. Metab., 1997, 11(3) 585-595 | |
| | | LI, et al., Aminoacylpyrrolidine-2-nitriles: Potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26), Archives of Biochem. and Bioph., 323(1)148-154 (1995). | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/99. OMB 0651-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|---|---|----|--------------------------|-------------------------|
| Substitute for form 1449B/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/035,783 |
| | | | Filing Date | 12/24/2001 |
| | | | First Named Inventor | GRAUPE |
| | | | Group Art Unit | 1626 |
| | | | Examiner Name | Shaio |
| | | | Attorney Docket Number | USAV2001/0081 - US - NP |
| Sheet | 8 | of | 13 | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | LIPSHUTZ, et al., Chiral induction in originally racemic amino acids via 5-acyl and 5-acyloxyaminooxazoles, <i>Isr. J. Chem.</i> 27(1):49-55 (1986), abstract. | |
| | | LIPSHUTZ, et al., Heterocycles as masked diamide/dipeptide equivalents. Formation and reactions of substituted 5-(acylamino)oxazoles as intermediates en route to the cyclopeptide alkaloids, <i>Am. Chem. Soc.</i> , 105(26):7703-7713 (1983). | |
| | | LIPSHUTZ, et al., Oxazolophanes as masked cyclopeptide alkaloid equivalents: cyclic peptide chemistry without peptide couplings, <i>J. Am. Chem. Soc.</i> , 112(18):7032-7041 (1990). | |
| | | MARQUIS, et al., Potent dipeptidylketone inhibitors of the cysteine protease cathepsin, <i>Chemical Abstracts</i> , 7:4 581-588 (1999). | |
| | | MCMATH, et al., Direct dialkylation of peptide nitriles. Application of the synthesis of 1-aminocyclopropane-1 carboxylic acid (Aoc)-containing dipeptides, <i>Bull. Soc. Chim. Fr.</i> 134(1):105-110 (1997). | |
| | | MORIYA, et al., Synthesis and Hypolipidemic Activities of 5-Thienyl-4-oxazoleacetic Acid Derivatives, <i>sup.1, J. Med. Chem.</i> , 29: 333-341 (1986). | |
| | | MOSER, et al., 130 Poly (dipeptamidinium)-Salze: definition und metoden zur preparativen herstellung. poly (dipeptamidinium) salts: definition and methods of preparation, <i>Helvetica Chimica ACTA, CH, Verlag, Basel</i> 69:1224-1262 (1986). | |
| | | NIPPON, K., Patent Abstracts of Japan, Publication No. 63301868, 013(137)(1988), abstract. | |
| | | NORTH, et al., Synthetic studies towards cyclic peptides. Concise synthesis of thiazoline and thiazole containing amino acids, <i>Tetrahedron</i> , 48(24):8627-8290 (1990). | |
| | | OGILVIE, et al., Peptidomimetic inhibitors of the human cytomegalovirus protease, <i>Journal of Medicinal Chemistry</i> vol. 40 No. 25 (1997). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/04B (10-98)
 Approved for use through 10/31/99. OMB 0661-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|-------------------------|
| Substitute for form 1449B/PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/035,783 | |
| | | | Filing Date | 12/24/2001 | |
| | | | First Named Inventor | GRAUPE | |
| | | | Group Art Unit | 1626 | |
| | | | Examiner Name | Shaio | |
| Sheet | 9 | of | 13 | Attorney Docket Number | USAV2001/0081 - US - NP |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | PICKEN, et al., Inhibition of bovine cathepsin B by amino acid-derived nitriles, Biochemical Society Transactions, vol. 18, No. 2, p:316 (1990). | |
| | | PLIURA, et al., Comparative behavior of calpain and cathepsin B, Biochem. J. vol. 288, pp. 759-762, 1992 | |
| | | POLMAN, et al., Drug treatment of multiple sclerosis, BMJ, 321: 19-26 (2000). | |
| | | RIESE, et al., Essential Role for Cathepsin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading, Immunity, 4: 357-366 (Apr. 1996). | |
| | | SMITH, et al., New Inhibitors of Cysteine Proteinases, J. Am. Chem. Soc. vol. 110, No. 13, pp. 4420-4431, 1988 | |
| | | SUAVE, et al., Carboxylmodified amino acids and peptides, I An efficient method for the synthesis of monofunctionalized enamines and monofunctionalized methyl ketone derivatives from thioamides via epieulides and thioiminium salts, Tetrahedron Lett, 29:19 2295-2298 (1988). | |
| | | SUZUE, S., Hepatic agents. I. Synthesis of aminocyl (and hydroxyacyl) aminoacetonitriles, Chem. and Pharm. Bull. (Tokyo) (1968), 16(8), 1417-32. | |
| | | SUZUE, et al., Studies on Hepatic Agents, Chem. Pharm. Bull. vol. 16, No. 8, pp. 1417-1432, Aug. 1968. | |
| | | SUZUKI, et al., Synthesis of 2-Aryl-4-(3-thienyl)imidazole Derivatives with Antiinflammatory Properties .sup.1), Chem. Pharm. Bull, 34(8): 3111-3120 (1998). | |
| | | TAO, et al., Inhibition of Calpain By Peptidyl Heterocycles, Bioorganic & Medicinal Chemistry Letters, 6:24 3009-3112 (1996). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-98)
 Approved for use through 10/31/99. OMB 0651-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|---|----|----|--------------------------|-------------------------|
| Substitute for form 1449B/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/035,783 |
| | | | Filing Date | 12/24/2001 |
| | | | First Named Inventor | GRAUPE |
| | | | Group Art Unit | 1626 |
| | | | Examiner Name | Shaio |
| | | | Attorney Docket Number | USAV2001/0081 - US - NP |
| Sheet | 10 | of | 13 | |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | THOMPSON, et al., Carboxyl-modified amino acids and peptides as protease inhibitors, J. Med. Chem., 29(1):104-111 (1986). | |
| | | TSUTSUMI, et al., Synthesis and Structure-Activity Relationships of Peptidyl α-Keto Heterocycles as Novel Inhibitors of Prolyl Endopeptidase, Journal of Medicinal Chemistry, vol. 37, No. 21, p 3492-3502 (1994). | |
| | | VARGHA, E., Peptide derivatives. VI. N-protected di- and tripeptide nitriles, Stud. Univ. Babes-Bolyai, Ser. Chem., 13(2):31-5 (English abstract of article in Romanian) (1968). | |
| | | VARGHESE, The structure and resonance Raman spectra--structure correlations for methoxycarbonyl-L-phenylalanyl-L-alanine ethyl dithioester, Can. J. Chem., 64(8):1668-1673 (1986). | |
| | | YAMADA, et al., Studies of unusual amino acids and their peptides. IX. The synthetic study of bomomycine B1 and B2, Bul. Chem. Soc., Jpn. 51(3):878-83 (1978), abstract. | |
| | | Derwent Abstract of Japanese Patent Application 08-192199, (Jul. 12, 1994). | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-98)
 Approved for use through 10/31/99. OMB 0651-0031
 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|----|--------------------------|-------------------------|
| Substitute for form 1449B/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/035,783 |
| | | Filing Date | 12/24/2001 |
| | | First Named Inventor | GRAUPE |
| | | Group Art Unit | 1626 |
| | | Examiner Name | Shalo |
| | | Attorney Docket Number | USAV2001/0081 - US - NP |
| Sheet | 12 | of | 13 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | CHAPMAN, et al., Emerging Roles for Cysteine Proteases In Human Biology, Ann. Rev. Physiol.; 1997; 59; pp.63-88. | |
| | | DRANOFF, et al., Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development, Immunity; 1999; 10; pp.197-208. | |
| | | FENWICK, et al., Diastereoselective Synthesis, Activity and Chiral Stability of Cyclo Alkoxyketone Inhibitors of Cathepsin K, Bioorg. Med. Chemm. Lett.; 2001; 11(2); pp.199-202. | |
| | | FENWICK, et al., Solid-phase Synthesis of Cyclic Alkoxyketones, Inhibitors of the Cysteine Protease Cathepsin K, Bioorg. Med. Chem. Lett.; 2001; 11(2); pp.195-198. | |
| | | GREENSPAN, et al., Identification of Dipeptidyl Nitriles as Potent and Selective Inhibitors of cathepsin B Through Structure-based Drug Design, J. Med. Chem.; 2001; 44; pp.4524-4534. | |
| | | LOWE, et al., Kinetic Specificity In Papain-catalyzed Hydrolyses, Biochem. J.; 1971; 124(1); pp.107-115. | |
| | | MACIEWICZ, et al., A comparison of Four Cathepsins (B, L, N and S) with Collagenolytic Activity From Rabbit Spleen, Biochem J.; 1998; 256; pp.433-440. | |
| | | MARQUIS, et al., Azetone-based Inhibitors of Human and Rat Cathepsin K, J. Med. Chem.; 2000; 44(9); pp.1380-1395. | |
| | | NAKAGAWA, et al., Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-induced Arthritis in Cathepsin S-null Mice, Immunity; 1999; 10; pp.207-217. | |
| | | OTTO, et al., Cysteine Proteases and their Inhibitors, Chem. Rev.; 1997; 97; pp.133-171. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐PTO/SB/088 (10-98)
Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|--------------------------|------------------------|-------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Complete If Known | | |
| | | | Application Number | 10/035,783 | |
| | | | Filing Date | 12/24/2001 | |
| | | | First Named Inventor | GRAUPE | |
| | | | Group Art Unit | 1626 | |
| | | | Examiner Name | Shalo | |
| Sheet | 13 | of | 13 | Attorney Docket Number | USAV2001/0081 - US - NP |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|--|--------------------------|---|----------------|
| Examiner Initials ¹ | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | SHI, et al., Molecular Cloning and Expression of Human Alveolar Macrophage Cathepsin S, an Elastolytic Cysteine Protease, J. Biol. Chem.; 1992; 267; pp.7258-7262. | |
| | | SINGH, et al., beta-lactams as Enzyme Inhibitors., IDrugs; 2000; 3(5); pp.512-517. | |
| | | VILLADANGOS, et al., Cathepsin S Activity Regulates Antigen Presentation and Immunity, J. Clin. Invest.; 1998; 101(10); pp.2351-2363. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.